Skip to main content
SpringerLink
Log in

Pharmacological Management of Arrhythmias in the Elderly

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The incidence of cardiac arrhythmia increases with advancing age, as does the prevalence of structural heart disease. Serious arrhythmias, such as sustained ventricular tachycardias, are uncommon in elderly patients, but nonsustained ventricular tachycardias and atrial fibrillation are relatively frequent.

The first step in the treatment of supraventricular and ventricular arrhythmias is the identification of an underlying (cardiac) disease, which should be treated appropriately. Patients with supraventricular arrhythmias who do not have a severe underlying cardiac disease may be treated with antiarrhythmic drugs to prevent recurrences of the arrhythmia. In selected patients, radiofrequency catheter ablation may nowadays be a first-line therapeutic strategy.

In elderly patients with underlying cardiac disease who are experiencing non-life-threatening arrhythmias, antiarrhythmic drugs are generally discouraged because of the risk of proarrhythmic effects or other adverse events. In patients experiencing life-threatening ventricular arrhythmias, β-blockers may be the first-line therapy. If these drugs are not effective, or cause adverse effects, class III or class IC antiarrhythmic drugs may be used as alternatives. Radiofrequency ablation is only moderately effective for haemodynamically stable ventricular tachycardias occurring post-myocardial infarction, but may be an option in drug-refractory patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kulbertus HE, de Leval-Rutten F, Bartsch P, et al. Atrial fibrillation in elderly, ambulatory patients. In: Kulbertus HE, Olsson SB, Schlepper M, editors. Atrial fibrillation. Mölndal: AB Hässle, 1981: 148–56

    Google Scholar 

  2. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation. N Engl J Med 1982; 306: 1018–22

    Article  PubMed  CAS  Google Scholar 

  3. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563–70

    Article  PubMed  CAS  Google Scholar 

  4. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24–38A

    Article  Google Scholar 

  5. Crijns HJGM, Van Wijk LM, Van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate: comparison of two regimens. Eur Heart J 1988; 9: 634–8

    PubMed  CAS  Google Scholar 

  6. Suttorp MJ, Kingma HJ, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–7

    Article  PubMed  CAS  Google Scholar 

  7. Fresco C, Proclemer A, on behalf of the PAFIT-2 Investigators. Management of recent onset atrial fibrillation. Eur Heart J 1996; 17Suppl. C: 41–7

    Article  PubMed  Google Scholar 

  8. Levine JH, Moganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type IA compared with IC antiarrhythmic drug therapy. Circulation 1989; 80: 1063–9

    Article  PubMed  CAS  Google Scholar 

  9. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987; 106: 503–6

    PubMed  CAS  Google Scholar 

  10. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the Diltiazem — Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63: 1046–51

    Article  PubMed  CAS  Google Scholar 

  11. Stambler BS, Wood MA, Ellenbogen KA, the Ibutilide Repeat Dose Study investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–21

    Article  PubMed  CAS  Google Scholar 

  12. Hou Z-Y, Chang M-S, Chen C-Y, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521–8

    PubMed  CAS  Google Scholar 

  13. Lown B. Electrical cardioversion of cardiac arrhythmias. Br Heart J 1967; 29: 469–87

    Article  PubMed  CAS  Google Scholar 

  14. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41–6

    Article  PubMed  Google Scholar 

  15. Van Gelder IC, Crijns HJGM, Heesen WF, et al. Atrial fibrillation in the elderly: is the same therapeutic strategy feasible [abstract]? J Am Coll Cardiol 1994; 23: 368A

    Google Scholar 

  16. Björk U, Karesoja M, Hirvonen P. Elective cardioversion in the elderly. In: Olsson SB, Allessie MA, Campbell RWF, editors. Atrial fibrillation: mechanisms and therapeutic strategies. Armonk (NY): Futura, 1994: 343–8

    Google Scholar 

  17. Carlsson J, Tebbe U, Rox J, et al., for the ALKK-Study group. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 1996; 78: 1380–4

    Article  PubMed  CAS  Google Scholar 

  18. Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Value and limitation of electrical cardioversion in patients with chronic atrial fibrillation — importance of arrhythmia risk factors and oral anticoagulation. Arch Intern Med 1996; 156: 2585–92

    Article  PubMed  Google Scholar 

  19. Tran HT. Torsades de pointes induced by nonantiarrhythmic drugs. Conn Med 1994; 58: 291–5

    PubMed  CAS  Google Scholar 

  20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–12

    Article  Google Scholar 

  21. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44: 1378–82

    Article  PubMed  CAS  Google Scholar 

  22. Lundstrom T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86–90

    Article  PubMed  CAS  Google Scholar 

  23. Robertson CE, Miller HC. Extreme tachycardia complicating the use of disopyramide in atrial flutter. Br Heart J 1980; 44: 602–3

    Article  PubMed  CAS  Google Scholar 

  24. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990; 66: 378–83

    Article  PubMed  CAS  Google Scholar 

  25. Juul-Möller S, Edvardsson N, Rehnquist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932–9

    Article  PubMed  Google Scholar 

  26. Crijns HJGM, Gosselink ATM, Van Gelder IC, et al. Drugs after cardioversion to prevent relapses of chronic atrial fibrillation. In: Kingma JH, van Hemel NM, Lie KI, editors. Atrial fibrillation: a treatable disease? Dordrecht: Kluwer Academic Publishers, 1992: 105–48

    Chapter  Google Scholar 

  27. Epstein LM, Chiesa N, Wong MN, et al. Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly. J Am Coll Cardiol 1994; 23: 1356–62

    Article  PubMed  CAS  Google Scholar 

  28. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1–5

    Google Scholar 

  29. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II: echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6–12

    Google Scholar 

  30. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147: 1561–4

    Article  PubMed  CAS  Google Scholar 

  31. Petersen P, Godtfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; I: 175–8

    Article  Google Scholar 

  32. Stroke Prevention in Atrial Fibrillation Study Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991; 84: 527–39

    Article  Google Scholar 

  33. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11

    Article  Google Scholar 

  34. Connolly SJ, Laupacis A, Gent M, et al. for the CAFA Study Coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349–55

    Article  PubMed  CAS  Google Scholar 

  35. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–12

    Article  PubMed  CAS  Google Scholar 

  36. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687–91

    Google Scholar 

  37. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention of Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–8

    Article  Google Scholar 

  38. Crijns HJGM, Van Gelder IC, Tieleman RG, et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997; 77: 56–61

    PubMed  CAS  Google Scholar 

  39. Kirkorian G, Moncada E, Chevalier P, et al. Radiofrequency ablation of atrial flutter: efficacy of an anatomically guided approach. Circulation 1994; 90: 2804–14

    Article  PubMed  CAS  Google Scholar 

  40. Philippon F, Plumb VJ, Epstein AE, et al. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. Circulation 1995; 92: 430–5

    Article  PubMed  CAS  Google Scholar 

  41. Poty H, Saoudi N, Aziz AA, et al. Radiofrequency catheter ablation of type 1 atrial flutter: prediction of late success by electrophysiological criteria. Circulation 1995; 92: 1389–92

    Article  PubMed  CAS  Google Scholar 

  42. Fischer B, Haissaguerre M, Garrigues S, et al. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25: 1365–72

    Article  PubMed  CAS  Google Scholar 

  43. Cosio FG, Arribas F, Lopez-Gil M, et al. Radiofrequency ablation of atrial flutter. J Cardiovasc Electrophysiol 1996; 7: 60–70

    Article  PubMed  CAS  Google Scholar 

  44. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108 (4 Suppl.): 352S–9S

    Article  PubMed  CAS  Google Scholar 

  45. Pentinga ML, Meeder JG, Crijns HJGM, et al. Late onset atrioventricular nodal tachycardia. Int J Cardiol 1993; 38: 293–8

    Article  PubMed  CAS  Google Scholar 

  46. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias: results and mechanisms. Circulation 1994; 89: 1074–89

    Article  PubMed  CAS  Google Scholar 

  47. Aronow WS, Epstein S, Koenigsberg M, et al. Usefulness of echocardiographic abnormal left ventricular ejection fraction, paroxysmal ventricular tachycardia, and complex ventricular arrhythmias in predicting new coronary events in patients over 62 years of age. Am J Cardiol 1988; 61: 1349–51

    Article  PubMed  CAS  Google Scholar 

  48. Aronow WS, Epstein S. Usefulness of silent ischemia, ventricular tachycardia, and complex ventricular arrhythmias in predicting new coronary events in elderly patients with coronary artery disease or systemic hypertension. Am J Cardiol 1990; 65: 511–2

    Article  PubMed  CAS  Google Scholar 

  49. Aronow WS, Epstein S, Koenigsberg M, et al. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988; 62: 1124–5

    Article  PubMed  CAS  Google Scholar 

  50. Buxton AE, Marchlinsky FE, Waxman HL, et al. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984; 53: 1275–9

    Article  PubMed  CAS  Google Scholar 

  51. Wiesfeld ACP, Crijns HJGM, Tuininga YS, et al. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol 1996; 19: 1026–35

    Article  PubMed  CAS  Google Scholar 

  52. Brodsky MA, Orlov MV, Allen BJ, et al. Clinical assessment of adrenergic tone and responsiveness to beta-blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease. Am Heart J 1996; 131: 51–8

    Article  PubMed  CAS  Google Scholar 

  53. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients: the Beta-Blocker Heart Attack Trial experience. Circulation 1983; 67Suppl. I: 194–7

    Google Scholar 

  54. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients aged 65–75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179–84

    Article  PubMed  CAS  Google Scholar 

  55. Aronow WS, Ahn C, Mercando AD, et al. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994; 74: 819–21

    Article  PubMed  CAS  Google Scholar 

  56. The ESVEM Investigators. Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiology Study Versus Electrocardiographic Monitoring trial. Circulation 1993; 87: 323–9

    Article  Google Scholar 

  57. Pfisterer M, Kiowski W, Burckhardt D, et al. Beneficial effects of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399–402

    Article  PubMed  CAS  Google Scholar 

  58. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991; 84: 550–7

    Article  PubMed  CAS  Google Scholar 

  59. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–8

    Article  PubMed  CAS  Google Scholar 

  60. Singh SN, Fletcher RD, Gross Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82

    Article  PubMed  CAS  Google Scholar 

  61. Stevenson WG, Khan H, Sager P, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993; 88: 1647–70

    Article  PubMed  CAS  Google Scholar 

  62. Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994; 23: 1333–41

    Article  PubMed  CAS  Google Scholar 

  63. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–40

    Article  PubMed  CAS  Google Scholar 

  64. Block M, Hammel D, Böcker D, et al. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? Am J Cardiol 1996; 78Suppl. 5A: 62–8

    Article  PubMed  CAS  Google Scholar 

  65. Kim SG. Values and limitations of programmed stimulation and ambulatory monitoring in the management of ventricular tachycardia. Am J Cardiol 1988; 62: 71–121

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Thoraxcenter, University Hospital Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands

    Isabelle C. Van Gelder, Johan Brügemann & Harry J. G. M. Crijns

Authors
  1. Isabelle C. Van Gelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johan Brügemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harry J. G. M. Crijns
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Gelder, I.C., Brügemann, J. & Crijns, H.J.G.M. Pharmacological Management of Arrhythmias in the Elderly. Drugs & Aging 11, 96–110 (1997). https://doi.org/10.2165/00002512-199711020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711020-00002

Keywords

Search

Navigation